Raynaud's disease

disorder

SNOMED 195295006CUI C0034734

Overview

Source: MedlinePlus.gov, National Library of Medicine. Not a substitute for medical advice.

Treatments & Interventions

Isoxsuprine hydrochloride

substance

Tolazoline hydrochloride

substance

Papaverine hydrochloride

substance

Nylidrin hydrochloride

substance

Buphenine

substance

Tolazoline

substance

Papaverine

substance

Isoxsuprine

substance

Captopril

substance

Prazosin hydrochloride

substance

Prazosin

substance

Lercanidipine hydrochloride

substance

Lercanidipine

substance

Clinical Trials

Total Trials

Recruiting

With Results

Recent Trials

Botulinum Toxin in Raynaud's Phenomenon

NCT05125029Phase 4Recruiting36 enrolled

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

NCT00048776Phase 4Completed75 enrolled

Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

NCT00048763Phase 4Completed75 enrolled

View all 3 trials on ClinicalTrials.gov

Signs & Symptoms

Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.

Raynaud phenomenon

HP:0030880

Skeletal anomalies

HP:0000924

Related Conditions

Vascular disorder of extremity(parent)

Disease of non-coronary systemic artery(parent)

Quick Facts

SNOMED CT: 195295006
UMLS CUI: C0034734
Fully Specified Name: Raynaud's disease (disorder)
Specialists: 0
Diagnostic Biomarkers: 0
HPO Phenotypes: 2
Known Treatments: 13
Clinical Trials: 3

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.